Centaurus Financial, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Centaurus Financial, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Sep 20, 2024	BUY	$38.96 - $42.75 $109,088 - $119,700	2,800 New	2,800 $114,000
Q4 2023 Feb 26, 2024	BUY	$20.27 - $42.44 $56,756 - $118,832	2,800 New	2,800 $118,000
Q2 2022 Aug 02, 2022	SELL	$20.62 - $37.15 $61,860 - $111,450	-3,000 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$23.5 - $35.38 $70,500 - $106,140	3,000 New	3,000 $105,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

Stay updated on Centaurus Financial, Inc. with notifications on news.